| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/05/2007 | US20070078146 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma |
| 04/05/2007 | US20070078145 sodium channel modulators such as 4-{4-[3-(2,4-Dichloro-phenoxy)-propyl]-1H-imidazol-2-yl}-N-thiazol-2-yl-benzenesulfonamide; central or peripheral nervous system disorders, pain; neuropathy, inflammation |
| 04/05/2007 | US20070078144 Agents for treating neurodegenerative diseases |
| 04/05/2007 | US20070078143 Method for preparing Ziprasidone monohydrochloride-hydrate |
| 04/05/2007 | US20070078142 Treatment of tuberous sclerosis associated neoplasms |
| 04/05/2007 | US20070078141 Piperazine amidines as antiviral agents |
| 04/05/2007 | US20070078140 MET kinase inhibitors |
| 04/05/2007 | US20070078139 Phosphodiesterase 4 inhibitors |
| 04/05/2007 | US20070078138 Analogs of dehydrophenylahistins and their therapeutic use |
| 04/05/2007 | US20070078137 Method of inhibiting neurotrophin-receptor binding |
| 04/05/2007 | US20070078136 Fused heterocyclic compounds useful as kinase modulators |
| 04/05/2007 | US20070078135 Substituted heteroaryl CB1 antagonists |
| 04/05/2007 | US20070078134 Treating sleep disorders insomnia; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-chloro-phenyl)-urea; restless leg syndrome, cardiovascular disorders, reducing blood clot |
| 04/05/2007 | US20070078133 Useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands; for example, 5-{4-[3-({2R}-2-methyl-pyrrolidin-1-yl)-cis-cyclobutyl]-phenyl}-pyrimidine |
| 04/05/2007 | US20070078132 tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer |
| 04/05/2007 | US20070078131 p38 mitogen-activated protein (MAP) kinase inhibitors such as Ethyl 3-(3-methylbenzoyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate, used in the treatment and/or prevention of autoimmune diseases or inflammatory disorders; antiinflammatory agents |
| 04/05/2007 | US20070078130 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases |
| 04/05/2007 | US20070078129 Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 04/05/2007 | US20070078128 5-[6-Chloro-2-fluoro-3-((R)-5-methyl-6-oxo-1,4,5,6-tetrahydro-[1,2,4]triazin-3-ylmethyl)-phenoxy]-isophthalonitrile; contacting a phenylacetic acid compound with an amino acid ester in presence of a coupling reagent to produce an intermediate, then with Lawesson's reagent, finally with hydrazine; AIDS |
| 04/05/2007 | US20070078127 Control of arthropods in animals |
| 04/05/2007 | US20070078126 Compounds, compositions and methods |
| 04/05/2007 | US20070078125 Arylamine mch r1 antagonists |
| 04/05/2007 | US20070078124 1-Aza-2-oxa-dibenzo(e,h)azulenes and their use for the treatment of central nervous system diseases and disorders |
| 04/05/2007 | US20070078123 1-Thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders |
| 04/05/2007 | US20070078122 Indolobenzazepine HCV NS5B inhibitors |
| 04/05/2007 | US20070078121 Enzyme modulators and treatments |
| 04/05/2007 | US20070078120 Novel piperidine derivative |
| 04/05/2007 | US20070078119 Storage system for texaphyrin pharmaceutical formulations |
| 04/05/2007 | US20070078117 Treating a traumatic brain injury by administering progesterone; dosing regime is constant or two-level, e.g., administering a higher hourly dose followed by a second time period during which a lower hourly dose is administered |
| 04/05/2007 | US20070078116 Method of treatment of otitis externa |
| 04/05/2007 | US20070078115 Phytosterol and/or phytostanol derivatives |
| 04/05/2007 | US20070078114 Combination therapy for alzheimer's disease and other diseases |
| 04/05/2007 | US20070078113 Oxygen antagonists; reducing agent, preservatives; enhancing survivability and achieving stasis or pre-stasis in cells or tissues; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer |
| 04/05/2007 | US20070078112 Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals |
| 04/05/2007 | US20070078111 LPA2 receptor agonist inhibitors of CFTR |
| 04/05/2007 | US20070078109 Compositions and methods used to treat acne and candida |
| 04/05/2007 | US20070078108 Liquid composition for bulging mucous membrane for use in endoscopic surgery comprising a chitosan derivative containing carbohydrate chains |
| 04/05/2007 | US20070078107 Skin disorders; administering drug in complex with phospholipid |
| 04/05/2007 | US20070078106 A 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil; 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl andhalo-substituted C2-6 alkynyl; antitumor agents; anticarcinogenic agents |
| 04/05/2007 | US20070078104 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis; antiinflammatory agents |
| 04/05/2007 | US20070078103 Formulations comprising antisense nucleotides to connexins |
| 04/05/2007 | US20070078099 Method of preventing, treating and diagnosing disorders of protein aggregation |
| 04/05/2007 | US20070078098 N-[3-(4-{(2S,3R)-2-(-(4-{[(2S, 5S, 3R, 4R, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)perhydro-2H-pyran-2-yl]ethyl-2-yl}phenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phenyl)propyl]-N-methylmethanesulfonamide; anticholesterol agent; low density lipoprotein; treating atherosclerosis |
| 04/05/2007 | US20070078097 provides a relief from peripheral arterial disease, no side effect, improving quality of life |
| 04/05/2007 | US20070078095 Compounds and methods for delivery of prostacyclin analogs |
| 04/05/2007 | US20070078093 Methods and compositions for treating cancer |
| 04/05/2007 | US20070078091 Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate |
| 04/05/2007 | US20070078087 Use of factor VIIa or factor VIIa equivalents for treating trauma |
| 04/05/2007 | US20070078083 MODULATION OF NEUORGENESIS BY HDac INHIBITION |
| 04/05/2007 | US20070078082 Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| 04/05/2007 | US20070078080 N4-Acylcytosine Nucleosides for Treatment of Viral Infections |
| 04/05/2007 | US20070078076 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 04/05/2007 | US20070077602 GPR35 and modulators thereof for the treatment of metabolic-related disorders |
| 04/05/2007 | US20070077586 Maternal Chelation for Embryo, Fetal, and Infant Benefit |
| 04/05/2007 | US20070077583 Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
| 04/05/2007 | US20070077314 Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| 04/05/2007 | US20070077313 Toleration iron supplement compositions |
| 04/05/2007 | US20070077310 Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| 04/05/2007 | US20070077307 Pharmaceutical compositions |
| 04/05/2007 | US20070077302 Methods for stabilizing ophthalmic compositions |
| 04/05/2007 | US20070077301 Venlafaxine osmotic device formulation |
| 04/05/2007 | US20070077300 Oral compositions containing a salivation inducing agent |
| 04/05/2007 | US20070077299 Oral formulation for 5-ht-receptor agonists, uses and methods of treatment employing the same |
| 04/05/2007 | US20070077297 Modified release ibuprofen dosage form |
| 04/05/2007 | US20070077296 Pharmaceutical Preparation containing Meloxicam |
| 04/05/2007 | US20070077295 Method and composition for pharmaceutical product |
| 04/05/2007 | US20070077294 Capsules comprising topiramate |
| 04/05/2007 | US20070077292 Compositions and methods for improved skin care |
| 04/05/2007 | US20070077290 High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| 04/05/2007 | US20070077288 Transdermal delivery of non-steroidal anti-inflammatory drugs |
| 04/05/2007 | US20070077286 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| 04/05/2007 | US20070077285 Adhesive skin patch |
| 04/05/2007 | US20070077284 Transdermal formulation comprising an opioid analgesic and an aloe composition |
| 04/05/2007 | US20070077278 Polysaccharide-containing composition and tear film stabilizing ophthalmic solution |
| 04/05/2007 | US20070077277 Compositions and uses thereof |
| 04/05/2007 | US20070077273 Microfabricated nanopore device for sustained release of therapeutic agent |
| 04/05/2007 | US20070077269 Method of birth control and hormone regulation |
| 04/05/2007 | US20070077268 Hydrophobic carrier modified implants for beneficial agent delivery |
| 04/05/2007 | US20070077267 Bioactive composite implants |
| 04/05/2007 | US20070077261 Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers |
| 04/05/2007 | US20070077258 ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS |
| 04/05/2007 | US20070077251 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 04/05/2007 | US20070077244 Inhibitor protein of the wnt signal pathway |
| 04/05/2007 | US20070077234 Regulation of T cell-mediated immunity by tryptophan |
| 04/05/2007 | US20070077230 Method for the pre-conditioning/fixation and treatment of diseases with heat activation/release with thermo-activated drugs and gene products |
| 04/05/2007 | US20070077228 Method of treating or retarding the development of blindness |
| 04/05/2007 | US20070077225 Continuous delivery methods for treating hepatitis virus infection |
| 04/05/2007 | US20070077224 Regulation of T cell-mediated immunity by tryptophan |
| 04/05/2007 | US20070077220 Stable ascorbic acid compositions |
| 04/05/2007 | US20070077219 Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 04/05/2007 | US20070077215 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening |
| 04/05/2007 | US20070077210 cyclodextrins |
| 04/05/2007 | US20070077209 Stabilized particle dispersions containing nanoparticles |
| 04/05/2007 | US20070077208 Pharmaceutical foam |
| 04/05/2007 | US20070077207 Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
| 04/05/2007 | US20070077203 Surrogate markers |
| 04/05/2007 | US20070077197 Cancer diagnosis; antitumor agents, radiotherapy |
| 04/05/2007 | DE60124600T2 Zusammensetzungen und Verfahren zur Behandlung von Zuständen, die auf Östrogen ansprechen Compositions and methods for treating conditions responsive to estrogen |
| 04/05/2007 | DE4393944B4 Use of ecdysteroid in cosmetic or dermatological compsns or culture media - to stimulate differentiation of keratinocytes, e.g. for treating psoriasis or ichthyosis and in prepn of skin grafts |
| 04/05/2007 | DE102005047563A1 New modification of specific substituted thiophene carboxamide, useful for prevention and treatment of thrombo-embolic disease, has higher solubility than known modifications |